BridgeBio Oncology Therapeutics
Pre-clinicalRedefining what’s possible in precision oncology to treat RAS-dependent cancers. Inhibiting Active RAS. Going beyond current approaches.
Founded
2019
Focus
Small Molecules
About
Redefining what’s possible in precision oncology to treat RAS-dependent cancers. Inhibiting Active RAS. Going beyond current approaches.
Funding History
2Total raised: $125M
Series B$75MCormorant Asset ManagementFeb 15, 2023
Series A$50MBridgeBio PharmaApr 15, 2021
Company Info
TypePrivate
Founded2019
LocationPalo Alto, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile